ME02930B - Metode za lečenje imunskih poremećaja povezanih sa transplantacijom grafta sa solubilnim ctla4 mutantnim molekulima - Google Patents
Metode za lečenje imunskih poremećaja povezanih sa transplantacijom grafta sa solubilnim ctla4 mutantnim molekulimaInfo
- Publication number
- ME02930B ME02930B MEP-2017-162A MEP16217A ME02930B ME 02930 B ME02930 B ME 02930B ME P16217 A MEP16217 A ME P16217A ME 02930 B ME02930 B ME 02930B
- Authority
- ME
- Montenegro
- Prior art keywords
- methods
- disorders associated
- immune disorders
- mutant molecules
- soluble ctla4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Alternative & Traditional Medicine (AREA)
- Transplantation (AREA)
- Medical Informatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66877405P | 2005-04-06 | 2005-04-06 | |
PCT/US2006/012648 WO2006108035A1 (en) | 2005-04-06 | 2006-04-05 | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
EP06749324.7A EP1868635B1 (en) | 2005-04-06 | 2006-04-05 | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
ME02930B true ME02930B (me) | 2018-04-20 |
Family
ID=36694299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2017-162A ME02930B (me) | 2005-04-06 | 2006-04-05 | Metode za lečenje imunskih poremećaja povezanih sa transplantacijom grafta sa solubilnim ctla4 mutantnim molekulima |
Country Status (25)
Country | Link |
---|---|
US (2) | US7482327B2 (me) |
EP (1) | EP1868635B1 (me) |
JP (1) | JP2008535841A (me) |
KR (1) | KR101235484B1 (me) |
CN (1) | CN101198347A (me) |
AR (1) | AR055052A1 (me) |
AU (1) | AU2006231622B2 (me) |
BR (1) | BRPI0608144A2 (me) |
CA (1) | CA2603970A1 (me) |
CY (1) | CY1119145T1 (me) |
DK (1) | DK1868635T3 (me) |
EA (1) | EA013122B1 (me) |
ES (1) | ES2634260T3 (me) |
HR (1) | HRP20171121T8 (me) |
IL (1) | IL186189A (me) |
LT (1) | LT1868635T (me) |
ME (1) | ME02930B (me) |
MX (1) | MX2007012222A (me) |
NO (1) | NO342966B1 (me) |
NZ (2) | NZ561655A (me) |
PL (1) | PL1868635T3 (me) |
PT (1) | PT1868635T (me) |
RS (1) | RS56138B1 (me) |
SI (1) | SI1868635T1 (me) |
WO (1) | WO2006108035A1 (me) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
SI1868635T1 (sl) * | 2005-04-06 | 2017-07-31 | Bristol-Myers Squibb Company | Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami |
US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
WO2008014035A2 (en) * | 2006-07-25 | 2008-01-31 | The Regents Of The University Of California | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
ES2399088T3 (es) | 2007-11-01 | 2013-03-25 | Perseid Therapeutics Llc | Polipéptidos y ácidos nucleicos inmunosupresores |
US20110223188A1 (en) * | 2008-08-25 | 2011-09-15 | Solomon Langermann | Targeted costimulatory polypeptides and methods of use to treat cancer |
WO2010049935A1 (en) * | 2008-10-30 | 2010-05-06 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
US20100297123A1 (en) * | 2009-05-15 | 2010-11-25 | Garrison Fathman C | Combination therapy to inhibit t cell effector function |
TW201134481A (en) | 2010-03-12 | 2011-10-16 | Abbott Biotherapeutics Corp | CTLA4 proteins and their uses |
ES2589678T3 (es) | 2010-09-08 | 2016-11-15 | Yeda Research And Development Co. Ltd. | Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma |
US20130183322A1 (en) | 2010-09-08 | 2013-07-18 | Yeda Research And Development Co., Ltd. | Immunosuppressive drug combination for a stable and long term engraftment |
SG11201400513PA (en) | 2011-09-08 | 2014-06-27 | Yeda Res & Dev | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
SG10201610288TA (en) | 2011-10-13 | 2017-02-27 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40l |
JP2016515706A (ja) | 2013-03-28 | 2016-05-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 共刺激遮断抵抗性拒絶のリスクがある患者を同定するための方法 |
CN104673822A (zh) * | 2013-11-27 | 2015-06-03 | 深圳先进技术研究院 | 一种重组载体及其制备方法和应用 |
CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
US20170051059A1 (en) | 2014-03-19 | 2017-02-23 | Bristol-Myers Squibb Company | Methods of treating transplant rejection using a domain antibody directed against cd40 |
WO2016168771A2 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
CA2991690A1 (en) | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory t cells and use of same in immunotherapy |
US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
US11555178B2 (en) | 2017-01-18 | 2023-01-17 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
US10286036B2 (en) | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
KR20230020022A (ko) | 2017-10-10 | 2023-02-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
US11925640B2 (en) | 2018-06-22 | 2024-03-12 | Mayo Foundation For Medical Education And Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
EP3818147A4 (en) * | 2018-07-06 | 2021-11-24 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS TO IMPROVE TRANSPLANT SUCCESS |
BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
CN115089718B (zh) * | 2021-11-30 | 2024-05-28 | 杭州瑞普晨创科技有限公司 | 用于异种移植的免疫抑制剂组合和免疫抑制方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
AU661854B2 (en) | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
CA2436139A1 (en) * | 2001-01-26 | 2002-08-01 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
ES2302811T3 (es) * | 2001-05-23 | 2008-08-01 | Bristol-Myers Squibb Company | Procedimiento para proteger transplantes de islotes alogenicos usando moleculas mutantes soblules ctla4. |
AU2003243152A1 (en) * | 2002-04-19 | 2003-11-03 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
CN101857851A (zh) | 2002-12-23 | 2010-10-13 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法 |
BR0316882A (pt) | 2002-12-23 | 2005-10-25 | Bristol Myers Squibb Co | Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
SI1868635T1 (sl) * | 2005-04-06 | 2017-07-31 | Bristol-Myers Squibb Company | Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami |
-
2006
- 2006-04-05 SI SI200632175A patent/SI1868635T1/sl unknown
- 2006-04-05 ES ES06749324.7T patent/ES2634260T3/es active Active
- 2006-04-05 BR BRPI0608144-4A patent/BRPI0608144A2/pt not_active Application Discontinuation
- 2006-04-05 RS RS20170794A patent/RS56138B1/sr unknown
- 2006-04-05 CA CA002603970A patent/CA2603970A1/en not_active Abandoned
- 2006-04-05 NZ NZ561655A patent/NZ561655A/en not_active IP Right Cessation
- 2006-04-05 LT LTEP06749324.7T patent/LT1868635T/lt unknown
- 2006-04-05 EA EA200702180A patent/EA013122B1/ru active IP Right Revival
- 2006-04-05 EP EP06749324.7A patent/EP1868635B1/en active Active
- 2006-04-05 PL PL06749324T patent/PL1868635T3/pl unknown
- 2006-04-05 KR KR1020077025644A patent/KR101235484B1/ko active IP Right Grant
- 2006-04-05 CN CNA2006800198976A patent/CN101198347A/zh active Pending
- 2006-04-05 JP JP2008505489A patent/JP2008535841A/ja active Pending
- 2006-04-05 WO PCT/US2006/012648 patent/WO2006108035A1/en active Application Filing
- 2006-04-05 PT PT67493247T patent/PT1868635T/pt unknown
- 2006-04-05 AU AU2006231622A patent/AU2006231622B2/en active Active
- 2006-04-05 DK DK06749324.7T patent/DK1868635T3/en active
- 2006-04-05 MX MX2007012222A patent/MX2007012222A/es active IP Right Grant
- 2006-04-05 ME MEP-2017-162A patent/ME02930B/me unknown
- 2006-04-06 US US11/399,666 patent/US7482327B2/en active Active
- 2006-04-06 AR ARP060101377A patent/AR055052A1/es unknown
-
2007
- 2007-09-23 IL IL186189A patent/IL186189A/en active IP Right Grant
- 2007-10-09 NO NO20075078A patent/NO342966B1/no unknown
-
2008
- 2008-11-19 US US12/313,342 patent/US20100041602A1/en not_active Abandoned
-
2009
- 2009-04-21 NZ NZ576434A patent/NZ576434A/en not_active IP Right Cessation
-
2017
- 2017-07-21 HR HRP20171121TT patent/HRP20171121T8/hr unknown
- 2017-07-28 CY CY20171100812T patent/CY1119145T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171121T8 (hr) | Metode za liječenje imunoloških poremećaja povezanih sa transplatacijom grafta sa solubilnim ctla4 mutiranim molekulama | |
NL301145I1 (me) | ||
HK1204994A1 (en) | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity | |
IL186895A0 (en) | Methods for treating eye conditions | |
RS55888B1 (sr) | Tweak vezujuća antitela | |
EP2083857A4 (en) | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA | |
AU2006279280A8 (en) | Methods and compositions for treating neurological disease | |
EP1874342A4 (en) | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | |
EP1827450A4 (en) | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE | |
IL183985A0 (en) | Methods for treating autoimmune disorders | |
GB0818413D0 (en) | CD47 Related compositions and methods for treating immunological diseases and disorders | |
EP1827604A4 (en) | METHODS AND COMPOSITIONS FOR ADOPTIVE IMMUNOTHERAPY | |
ZA200801564B (en) | Process for preparaing maytansinoid antibody conjugates | |
WO2006127900A3 (en) | Tl1a in the treatment of disease | |
EP1946256A4 (en) | METHODS FOR CHARACTERIZING GROUPS OF CONTENT ARTICLES | |
ZA200805760B (en) | Method for treating disseminated cancer | |
WO2007122382A3 (en) | Lycopene for the treatment of metabolic dysfunction | |
EP1878521A4 (en) | PART AND METHOD FOR THE PRODUCTION THEREOF | |
EP1883405A4 (en) | METHODS OF TREATING NEPHROLITHIASIS | |
EP1940436A4 (en) | METHODS OF TREATING NEUROLOGICAL DISEASES OF IMMUNE ORIGIN | |
EP1968563A4 (en) | TREATMENT METHODS USING TRIARYLMETHANE COMPOUNDS | |
IL194373A0 (en) | Methods for treating kidney disorders | |
WO2008063957A3 (en) | Cblb for treating endotoxin-mediated disorders | |
IL188127A0 (en) | Methods for treating demyelination disorders | |
EP2211656A4 (en) | GEMSTONES AND METHOD FOR CONTROLLING THEIR APPEARANCE |